It mitigates isoproterenol-induced cardiac hypertrophy by reducing brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and β-myosin heavy chain (β-MHC) levels through suppression of the calcineurin/NFATc3 pathway (Tan et al., 2011). This evidence concerns the gene NPPA and cardiac hypertrophy.